The company’s platform, the NewStem Software Diagnostic Device, provides information to oncologists regarding the presence of mutations in a patient’s tumor profile that may confer resistance to certain anti-cancer drugs, according to a Dec. 14 press release NovelStem International shared with Becker’s.
MSK Innovation Hub will work together with the company to develop new ways to bring better treatments to cancer patients and help build out and commercialize NovelStem’s platform.
